

الآية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال تعالى:

اقْرَأْ بِاسْمِ رَبِّكَ الَّذِي خَلَقَ (1) خَلَقَ الْإِنْسَانَ مِنْ عَلَقٍ (2) اقْرَأْ وَرَبُّكَ

الْأَكْرَمُ (3) الَّذِي عَلَّمَ بِالْقَلَمِ (4) عَلَّمَ الْإِنْسَانَ مَا لَمْ يَعْلَمْ (5)

صدق الله العظيم

سورة العلق الآيات (1-5)

DeDication

To my FaTher,

Mother,

Brothers,

SiSters, and

My true Friends

With admiration and respect

Acknowledgements

Praise and thanks were due to **ALMIGHTY ALLAH** who gives me health and power to complete this work.

I would like to express my sincere gratitude to my supervisor **Dr. Ali Mohammed El-Hassan El-Eragi, (Veterinary Research Institute)**, for his guidance valuable comment, and encouragement during the work.

Special thanks were due to my Colleagues' in **Alselah Altibbi Hospital Laboratories** for their close assistance in the practical work, particularly those in the **Microbiology Department** with special emphasis to **Mr. Mostafa Hassan**.

Special thanks and gratitude were due to the **Staff of Microbiology Department, University of Sudan for Science and Technology**.

Abstract

This study was carried out in Khartoum State in the period of time from April to July 2012 on a total of 183 patients in various haemodialysis centers to compare between the sensitivity and specificity of Immune chromatography test (ICT) and indirect HCV ELISA using recombinant antigens.

Sixty seven (36.6%) patients were positive for HCV-antibodies by ICT and Sixty eight (37.2%) patients were positive by ELISA.

However, this difference was not statistically significant (T. test, p value > 0.05). Therefore, both tests are reliable for screening HCV-antibodies in patients as far as a recombinant antigens were employed in both tests to ensure specificity.

مستخلص الدراسة

اجريت هذه الدراسة التى شملت 183 مريض فى ولاية الخرطوم فى عدة مراكز استشفاء دموى للمقارنة بين حساسية وخصوصية الاختبار بواسطة تقنية الكروماتوغرافى الممنع والاليزا غير المباشر لفيروس الكبد الوبائى من نوع (ج) .

بعد اجراء الاختبارات وجد ان سبع وستون (36.6%) عينه موجبة لمرض التهاب الكبد الوبائى من نوع (ج) باستعمال اختبار الكروماتوغرافى الممنع بينما وجدت ثمان وستون (37.2%) عينة موجبة من نفس المجموعة باستخدام الاليزا غير المباشر.

وجد ان هذا الفرق ليس معتبرا عند تحليل البيانات احصائيا باستخدام جدول (T. test) وبالتالى فان كلا الاختبارين يمكن الاعتماد عليهما فى الكشف عن الاجسام المضادة لالتهاب الكبد الفيروسي (ج) خاصة عند استعمال المستضد المؤشب فى كلا الاختبارين.

Table of Contents	Pag No
الآية	I
Dedication	II
Acknowledgements	III
Abstract	IV
مستخلص الدراسة	V
Table of Contents	VI
List of Tables	XI
List of Figures	XII
List of Abbreviations	XIII
Chapter One: Introduction	
1. Introduction	1
1.1 Rationale	3
1.2 Objectives	4
1.2.1 General Objective	4
1.2.2 Specific Objectives	4
Chapter Two: Literature Review	
2.1 History of HCV	5
2.2 Classification of HCV	5
2.3 Structure of HCV Virion	5
2.4 Genome Structure of HCV	6

2.5 Characteristics and Functions of HCV Proteins	7
2.5.1 Structural proteins	7
2.5.1.1 Core Proteins	7
2.5.1.2 Frame shift protein	7
2.5.2 Non Structural Proteins	8
2.5.2.1 P7	8
2.5.2.2 NS2	8
2.5.2.3 NS3-NS4A	8
2.5.2.4 NS4B	8
2.5.2.5 NS5A	8
2.5.2.6 NS5B (RNA-dependent RNA Polymerase)	9
2.6 Replication and growth cycle of the virus	9
2.6.1 HCV receptors	9
2.6.1.1 CD8-1	9
2.6.1.2 Scavenger receptor B type-1	9
2.6.1.3 Dendritic Cell-Specific Intracellular Adhesion Molecule grabbing non-integrin	10
2.6.1.4 Low Density Lipoprotein (LDL-P)	10
2.6.1.5 Asialoglycoprotein receptor	10
2.6.1.6 Glycosaminoglycans receptor	10
2.6.2 Mechanism of cell entry and fusion	10
2.6.3 Replication of HCV	11
2.7 Pathogenesis	12
2.8 Symptoms	14
2.9 Epidemiology of HCV	15
2.9.1 Transmission of HCV	15

2.9.1.1 Transfusion	15
2.9.1.2 Transplantation	16
2.9.1.3 Injection and other illegal drug use	16
2.9.1.4 Sexual transmission	16
2.9.1.5 Nosocomial and Occupational exposures	16
2.9.1.6 Vertical transmission	16
2.9.1.7 Body Fluids	17
2.9.2 Prevalence of HCV	17
2.9.2.1 Prevalence of HCV in Sudan	18
2.10 Laboratory diagnosis of HCV	19
2.10.1 Serological tests	19
2.10.1.1 Enzyme immune assay (EIA)	19
2.10.1.2 Recombinant immune blot assay (RIBA)	20
2.10.1.3 Immune chromatography test (ICT)	20
2.10.2 Nucleic acid tests	21
2.10.2.1 Polymerase chain reaction (PCR)	21
2.10.2.2 Viral load tests	21
2.10.2.3 Genotype tests	22
2.10.3 Liver function tests (LFT)	22
2.10.3.1 Aspartate aminotransferase (AST)	23
2.10.3.2 Alanine aminotransferase (ALT)	23
2.10.3.3 Albumin	23
2.10.3.4 Bilirubin	24
2.10.3.5 Prothrombin time (PT)	24
2.10.3.6 Alkaline phosphatase (AP)	24
2.10.4 Liver biopsy	24

2.11 Treatment	25
2.12 Prevention and Control	25
2.12.1 Stability of HCV	25
2.12.2 Passive Immunization	26
2.12.3 Active Immunization	26
2.13 HCV and haemodialysis Patients	26
Chapter Three: Materials and Methods	
3.1 Study design	30
3.1.1 Study location	30
3.1.2 Study population	30
3.1.3 Study duration	30
3.1.4 Sample size	30
3.1.5 Data Collection	30
3.1.6 Ethical consideration	31
3.1.7 Data analysis	31
3.1.8 Sample Collection	31
3.1.9 Inclusion criteria	31
3.1.10 Exclusion criteria	31
3.2 Laboratory investigations	32
3.2.1 Immune chromatography test for detection of HCV antibodies	32
3.2.1.1 Principle	32
3.2.1.2 Materials provided	32
3.2.1.3 Materials required but not provided	33
3.2.1.4 Storage and Stability	33
3.2.1.5 Test procedure	33
3.2.1.6 Interpretation of results	33

3.2.1.7 Performance characteristic	34
3.2.1.8 Specificity	34
3.2.1.9 Sensitivity	34
3.3.1 Indirect ELISA for the detection of HCV antibodies	34
3.3.1.1 Principle of Assay	34
3.3.1.2 ELISA Kits	35
3.3.1.3 Other materials not included in the kits	36
3.3.1.4 Storage of ELISA Kits	36
3.3.1.5 Assay Procedure	36
3.3.1.6 Reading of the test	37
3.3.1.7 Interpretation of the test	38
3.3.1.8 Diagnostic specificity	38
3.3.1.9 Diagnostic sensitivity	38
Chapter Four: Results	
4.1 ICT Results	41
4.2 ELISA Results	42
Chapter Five: Discussion	
Discussion	47
Conclusions	48
Recommendations	49
References	50
Appendices	

LIST OF TABLES

List of Tables	Page No.
Table 1 The effect of gender of haemodialysis patients on infection with HCV by ICT and ELISA Tests	43
Table 2 The effect of age of haemodialysis patients on infection with HCVby ICT and ELISA Tests	44
Table 3 Statistical comparison between ICT and ELISA Tests	45
Table 4 Kappa test	45
Table 5 Sensitivity and Specificity of ICT test	46
Table 6 Sensitivity and Specificity of ELISA test	46

LIST OF FIGURES

List of Figures	Page No.
Figure 1 Structure of HCV virus	6
Figure 2 Distribution of haemodialysis patients according to age groups	39
Figure 3 Distribution of haemodialysis patients according to gender	40
Figure 4 Detection of anti-HCV antibodies among haemodialysis patients by ICT	41
Figure 5 Detection of anti-HCV antibodies among haemodialysis patients by ELISA	42

List of Abbreviations

ALK: Alkaline phosphatase.

ALT: Alanine Aminotransferase.

AST: Aspartate Aminotransferase.

PT: Prothrombine Time.

ARFP: Alternate Reading Frame Protein.

b-DNA: Branched Deoxy ribonucleic Acid.

CAPD: Continuous Ambulatory Peritoneal Dialysis.

CD8-1: Cluster of Differentiation 8-1.

CDC: Center for Disease Control and Prevention.

CDNA: Complementary deoxyribonucleic Acid.

DC-SIGN: Dendritic Cell-Specific Intracellular Adhesion Molecule Grabbing Non-Integrin.

E: Envelop.

ICT: Immune Chromatography Test.

ELISA: Enzyme-Linked Immune Sorbent Assay.

F Protein: Frame shift protein.

GGT: Gamma Glutamyl Transpeptidase.

HBV: Hepatitis B Virus.

HCV: Hepatitis C Virus.

HCC: Hepato Cellular Carcinoma.

HRP: Horse Radish Peroxidase.

KKDC: Khartoum Kidney Dialysis Center.

LDL-R: Low Density Lipoprotein- Receptor.

OD: Optical Density.

PCR: Polymerase Chain Reaction.

RIBA: Recombinant Immune blot Assay.

RNA: Ribo Nucleic Acid.

RT-PCR: Reverse Transcriptase-PCR.

SGOT: Serum Glutamate Oxalocitate Transaminase.

SGPT: Serum Glutamate Pyruvate Transaminase.

QRT-PCR: Quantitative Real Time-PCR.